<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319147</url>
  </required_header>
  <id_info>
    <org_study_id>EAA</org_study_id>
    <nct_id>NCT03319147</nct_id>
  </id_info>
  <brief_title>Effect of Amino Acid on Muscle Damage</brief_title>
  <official_title>Effect of Leucine-enriched Essential Amino Acid on Integrated Muscle Protein Synthesis and Muscle Recovery After Resistance Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ajinomoto Co., Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the impact of essential amino acids on integrated&#xD;
      muscle protein synthesis over 4 days after resistance exercise.&#xD;
&#xD;
      In addition, the secondary objective is to determine the effect of essential amino acids on&#xD;
      satellite cell regulation and inflammatory responses during this prolonged recovery period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle protein synthesis</measure>
    <time_frame>4 hours</time_frame>
    <description>Skeletal muscle fractional synthesis rate (%/h) will be determined by oral pulse method using ring-[D5]phenylalanine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>exercise performance</measure>
    <time_frame>4 days</time_frame>
    <description>Maximal strength (torque in n-M) of the knee extensors will be assessed by a maximal isometric voluntary contraction (MVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle soreness</measure>
    <time_frame>4 days</time_frame>
    <description>Corresponding subjective ratings of muscle soreness will be collected from participants using a visual analogue scale (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle damage</measure>
    <time_frame>4 days</time_frame>
    <description>Muscle damage will be determined by histochemical analysis. muscle damage is defined as Z-band streaming.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4g of maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4g of essential amino acids</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Active</intervention_name>
    <description>4g of essential amino acids</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4g of maltdextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, male, recreationally-active participants&#xD;
&#xD;
          -  Healthy will be defined as screened by the PAR-Q+ (The Physical Activity Readiness&#xD;
             Questionnaire for everyone; Appendix. B). Active will be defined as being in the top&#xD;
             20% of age specific scores on iPAQ (the International Physical Activity Questionnaire;&#xD;
             Appendix.C).&#xD;
&#xD;
          -  Participants are required not to engage in lower limb RT (resistance training) for at&#xD;
             least 6 months prior to the study.&#xD;
&#xD;
          -  Participants will be 18-35 years old.&#xD;
&#xD;
          -  Participants are willing to abide by the compliance rules of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Inability to adhere to any of the compliance rules judged by principle investigator or&#xD;
             medical doctor&#xD;
&#xD;
          -  Self-reported regular tobacco use&#xD;
&#xD;
          -  Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.)&#xD;
&#xD;
          -  The individual who has allergy for milk&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Goldring Centre for High Performance Sport</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S2C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Daniel Moore</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>recovery</keyword>
  <keyword>muscle</keyword>
  <keyword>protein</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

